PP_1170x120_10-25-21

Eli Lilly and Co.’s ultra rapid lispro (URLi)

Lilly’s ultra rapid lispro provided similar A1C reductions compared to Humalog

Lilly’s ultra rapid lispro provided similar A1C reductions compared to Humalog

INDIANAPOLIS — Two phase 3 studies show that Eli Lilly and Co.’s ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog (insulin lispro) at 26 weeks in people with type 1 and type 2 diabetes. The data from these treat-to-target studies showed URLi also significantly reduced the rise in blood glucose one hour